Study identifier:D0110C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics o fAZD5438 Given Orally, in 2 dosing schedules, in Patients with Advanced Solid Malignancies.
solid tumour
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
-
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|